Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.13 USD | -4.05% | -23.93% | +66.41% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 139M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -46M | EV / Sales 2024 * | - |
Net cash position 2024 * | 94.2M | Net cash position 2025 * | 50.8M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.2
x | P/E ratio 2025 * |
-3.49
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.25% |
Latest transcript on Regulus Therapeutics Inc.
1 day | -4.05% | ||
1 week | -23.93% | ||
Current month | -26.04% | ||
1 month | -10.69% | ||
3 months | +74.59% | ||
6 months | +69.05% | ||
Current year | +66.41% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 19-08-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 17-05-31 |
David Baltimore
BRD | Director/Board Member | 86 | 08-12-31 |
Director/Board Member | 75 | 13-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 2.13 | -4.05% | 222,749 |
24-04-18 | 2.22 | -5.13% | 202,895 |
24-04-17 | 2.34 | -8.59% | 295,342 |
24-04-16 | 2.56 | -7.91% | 455,858 |
24-04-15 | 2.78 | -0.71% | 315,039 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.41% | 145M | |
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |
- Stock Market
- Equities
- RGLS Stock